3278 related articles for article (PubMed ID: 32507409)
1. Consensus summary report for CEPI/BC March 12-13, 2020 meeting: Assessment of risk of disease enhancement with COVID-19 vaccines.
Lambert PH; Ambrosino DM; Andersen SR; Baric RS; Black SB; Chen RT; Dekker CL; Didierlaurent AM; Graham BS; Martin SD; Molrine DC; Perlman S; Picard-Fraser PA; Pollard AJ; Qin C; Subbarao K; Cramer JP
Vaccine; 2020 Jun; 38(31):4783-4791. PubMed ID: 32507409
[TBL] [Abstract][Full Text] [Related]
2. The Long Road Toward COVID-19 Herd Immunity: Vaccine Platform Technologies and Mass Immunization Strategies.
Frederiksen LSF; Zhang Y; Foged C; Thakur A
Front Immunol; 2020; 11():1817. PubMed ID: 32793245
[TBL] [Abstract][Full Text] [Related]
3. SARS-CoV-2 SPIKE PROTEIN: an optimal immunological target for vaccines.
Salvatori G; Luberto L; Maffei M; Aurisicchio L; Roscilli G; Palombo F; Marra E
J Transl Med; 2020 Jun; 18(1):222. PubMed ID: 32493510
[TBL] [Abstract][Full Text] [Related]
4. Vaccine Candidates against Coronavirus Infections. Where Does COVID-19 Stand?
Al-Kassmy J; Pedersen J; Kobinger G
Viruses; 2020 Aug; 12(8):. PubMed ID: 32784685
[TBL] [Abstract][Full Text] [Related]
5. The 2020 Pandemic: Current SARS-CoV-2 Vaccine Development.
Alturki SO; Alturki SO; Connors J; Cusimano G; Kutzler MA; Izmirly AM; Haddad EK
Front Immunol; 2020; 11():1880. PubMed ID: 32973779
[TBL] [Abstract][Full Text] [Related]
6. A perspective on potential antibody-dependent enhancement of SARS-CoV-2.
Arvin AM; Fink K; Schmid MA; Cathcart A; Spreafico R; Havenar-Daughton C; Lanzavecchia A; Corti D; Virgin HW
Nature; 2020 Aug; 584(7821):353-363. PubMed ID: 32659783
[TBL] [Abstract][Full Text] [Related]
7. From SARS-CoV to SARS-CoV-2: safety and broad-spectrum are important for coronavirus vaccine development.
Ma C; Su S; Wang J; Wei L; Du L; Jiang S
Microbes Infect; 2020; 22(6-7):245-253. PubMed ID: 32437926
[TBL] [Abstract][Full Text] [Related]
8. Rapid COVID-19 vaccine development.
Graham BS
Science; 2020 May; 368(6494):945-946. PubMed ID: 32385100
[No Abstract] [Full Text] [Related]
9. Microneedle array delivered recombinant coronavirus vaccines: Immunogenicity and rapid translational development.
Kim E; Erdos G; Huang S; Kenniston TW; Balmert SC; Carey CD; Raj VS; Epperly MW; Klimstra WB; Haagmans BL; Korkmaz E; Falo LD; Gambotto A
EBioMedicine; 2020 May; 55():102743. PubMed ID: 32249203
[TBL] [Abstract][Full Text] [Related]
10. Development of an inactivated vaccine candidate for SARS-CoV-2.
Gao Q; Bao L; Mao H; Wang L; Xu K; Yang M; Li Y; Zhu L; Wang N; Lv Z; Gao H; Ge X; Kan B; Hu Y; Liu J; Cai F; Jiang D; Yin Y; Qin C; Li J; Gong X; Lou X; Shi W; Wu D; Zhang H; Zhu L; Deng W; Li Y; Lu J; Li C; Wang X; Yin W; Zhang Y; Qin C
Science; 2020 Jul; 369(6499):77-81. PubMed ID: 32376603
[TBL] [Abstract][Full Text] [Related]
11. A systematic review of SARS-CoV-2 vaccine candidates.
Dong Y; Dai T; Wei Y; Zhang L; Zheng M; Zhou F
Signal Transduct Target Ther; 2020 Oct; 5(1):237. PubMed ID: 33051445
[TBL] [Abstract][Full Text] [Related]
12. Vaccination against SARS-CoV-2 and disease enhancement - knowns and unknowns.
Zellweger RM; Wartel TA; Marks F; Song M; Kim JH
Expert Rev Vaccines; 2020 Aug; 19(8):691-698. PubMed ID: 32838605
[TBL] [Abstract][Full Text] [Related]
13. Coronavirus vaccines get a biotech boost.
Dance A
Nature; 2020 Jul; 583(7817):647-649. PubMed ID: 32694847
[No Abstract] [Full Text] [Related]
14. Rational Vaccine Design in the Time of COVID-19.
Burton DR; Walker LM
Cell Host Microbe; 2020 May; 27(5):695-698. PubMed ID: 32407707
[TBL] [Abstract][Full Text] [Related]
15. [Strategies for vaccine development of COVID-19].
Yang L; Tian D; Liu W
Sheng Wu Gong Cheng Xue Bao; 2020 Apr; 36(4):593-604. PubMed ID: 32347054
[TBL] [Abstract][Full Text] [Related]
16. A Novel Vaccine Employing Non-Replicating Rabies Virus Expressing Chimeric SARS-CoV-2 Spike Protein Domains: Functional Inhibition of Viral/Nicotinic Acetylcholine Receptor Complexes.
Stefano ML; Kream RM; Stefano GB
Med Sci Monit; 2020 May; 26():e926016. PubMed ID: 32463026
[TBL] [Abstract][Full Text] [Related]
17. What Would Jenner and Pasteur Have Done About COVID-19 Coronavirus? The Urges of a Vaccinologist.
Palatnik-de-Sousa CB
Front Immunol; 2020; 11():2173. PubMed ID: 32983183
[No Abstract] [Full Text] [Related]
18. The Brighton Collaboration standardized template for collection of key information for benefit-risk assessment of inactivated viral vaccines.
Kochhar S; Excler JL; Kim D; Robertson JS; Fast PE; Condit RC; Drew S; Wood D; Gurwith M; Klug B; Whelan M; Khuri-Bulos N; Mallett Moore T; Smith ER; Chen RT;
Vaccine; 2020 Sep; 38(39):6184-6189. PubMed ID: 32747214
[TBL] [Abstract][Full Text] [Related]
19. Mitigating Coronavirus Induced Dysfunctional Immunity for At-Risk Populations in COVID-19: Trained Immunity, BCG and "New Old Friends".
Kleen TO; Galdon AA; MacDonald AS; Dalgleish AG
Front Immunol; 2020; 11():2059. PubMed ID: 33013871
[TBL] [Abstract][Full Text] [Related]
20. What about the original antigenic sin of the humans versus SARS-CoV-2?
Roncati L; Palmieri B
Med Hypotheses; 2020 Sep; 142():109824. PubMed ID: 32408068
[No Abstract] [Full Text] [Related]
[Next] [New Search]
